Revance Therapeutics (RVNC) has released an update.
Revance Therapeutics, Inc. has set its 2024 corporate objectives, focusing on revenue targets for DAXXIFY® and RHA® Collection dermal fillers, payor coverage for DAXXIFY®, and regulatory milestones, with potential bonuses for executive officers tied to these goals. Additionally, the company has updated its Executive Severance Plan, providing severance benefits for key employees upon certain termination events, with specific provisions for the President and other executive officers, including adjustments related to Change in Control and definitions around Resignation for Good Reason.
For further insights into RVNC stock, check out TipRanks’ Stock Analysis page.
